^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lirafugratinib (RLY-4008)

    i
    Company:
    HLB Bio Group, Relay Therap
    Drug class:
    FGFR2 inhibitor
    Related drugs:
    Apply
    REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors (ReFocus) (NCT04526106)
    Phase 1/2
    Elevar Therapeutics
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    09/02/2020
    Primary completion :
    09/27/2024
    Completion :
    12/01/2027
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion
    |
    lirafugratinib (RLY-4008)